Proc SPIE Int Soc Opt Eng. 2011 Mar 4;7965:10.1117/12.891720. doi: 10.1117/12.891720. ABSTRACT Molecular imaging technologies are advancing rapidly and optical techniques in particular are set to play a large role in preclinical pharmaceutical testing. These approaches, however, are generally unable to quantify the level of expression of imaging probe reporters. In this study a novel…Continue Reading Quantifying receptor density <em>in vivo</em> using a dual-probe approach with fluorescence molecular imaging
Contrast enhanced-magnetic resonance imaging as a surrogate to map verteporfin delivery in photodynamic therapy
J Biomed Opt. 2013 Dec;18(12):120504. doi: 10.1117/1.JBO.18.12.120504. ABSTRACT The use of in vivo contrast-enhanced magnetic resonance (MR) imaging as a surrogate for photosensitizer (verteporfin) dosimetry in photodynamic therapy of pancreas cancer is demonstrated by correlating MR contrast uptake to ex vivo fluorescence images on excised tissue. An orthotopic pancreatic xenograft mouse model was used for…Continue Reading Contrast enhanced-magnetic resonance imaging as a surrogate to map verteporfin delivery in photodynamic therapy
Tumor endothelial marker imaging in melanomas using dual-tracer fluorescence molecular imaging
Mol Imaging Biol. 2014 Jun;16(3):372-82. doi: 10.1007/s11307-013-0692-1. Epub 2013 Nov 12. ABSTRACT PURPOSE: Cancer-specific endothelial markers available for intravascular binding are promising targets for new molecular therapies. In this study, a molecular imaging approach of quantifying endothelial marker concentrations (EMCI) is developed and tested in highly light-absorbing melanomas. The approach involves injection of targeted imaging…Continue Reading Tumor endothelial marker imaging in melanomas using dual-tracer fluorescence molecular imaging
Dynamic dual-tracer MRI-guided fluorescence tomography to quantify receptor density in vivo
Proc Natl Acad Sci U S A. 2013 May 28;110(22):9025-30. doi: 10.1073/pnas.1213490110. Epub 2013 May 13. ABSTRACT The up-regulation of cell surface receptors has become a central focus in personalized cancer treatment; however, because of the complex nature of contrast agent pharmacokinetics in tumor tissue, methods to quantify receptor binding in vivo remain elusive. Here,…Continue Reading Dynamic dual-tracer MRI-guided fluorescence tomography to quantify receptor density in vivo
Fluorescent affibody peptide penetration in glioma margin is superior to full antibody
PLoS One. 2013 Apr 12;8(4):e60390. doi: 10.1371/journal.pone.0060390. Print 2013. ABSTRACT OBJECT: Fluorescence imaging has the potential to significantly improve neurosurgical resection of oncologic lesions through improved differentiation between normal and cancerous tissue at the tumor margins. In order to successfully mark glioma tissue a fluorescent tracer must have the ability to penetrate through the blood…Continue Reading Fluorescent affibody peptide penetration in glioma margin is superior to full antibody
Dual-tracer background subtraction approach for fluorescent molecular tomography
J Biomed Opt. 2013 Jan;18(1):16003. doi: 10.1117/1.JBO.18.1.016003. ABSTRACT Diffuse fluorescence tomography requires high contrast-to-background ratios to accurately reconstruct inclusions of interest. This is a problem when imaging the uptake of fluorescently labeled molecularly targeted tracers in tissue, which can result in high levels of heterogeneously distributed background uptake. We present a dual-tracer background subtraction approach,…Continue Reading Dual-tracer background subtraction approach for fluorescent molecular tomography
Advantages of a dual-tracer model over reference tissue models for binding potential measurement in tumors
Phys Med Biol. 2012 Oct 21;57(20):6647-59. doi: 10.1088/0031-9155/57/20/6647. Epub 2012 Oct 1. ABSTRACT The quantification of tumor molecular expression in vivo could have a significant impact for informing and monitoring emerging targeted therapies in oncology. Molecular imaging of targeted tracers can be used to quantify receptor expression in the form of a binding potential (BP)…Continue Reading Advantages of a dual-tracer model over reference tissue models for binding potential measurement in tumors
Computed tomography-guided time-domain diffuse fluorescence tomography in small animals for localization of cancer biomarkers
J Vis Exp. 2012 Jul 17;(65):e4050. doi: 10.3791/4050. ABSTRACT Small animal fluorescence molecular imaging (FMI) can be a powerful tool for preclinical drug discovery and development studies. However, light absorption by tissue chromophores (e.g., hemoglobin, water, lipids, melanin) typically limits optical signal propagation through thicknesses larger than a few millimeters. Compared to other visible wavelengths,…Continue Reading Computed tomography-guided time-domain diffuse fluorescence tomography in small animals for localization of cancer biomarkers
Nanoparticle uptake in tumors is mediated by the interplay of vascular and collagen density with interstitial pressure
Nanomedicine. 2013 Feb;9(2):151-8. doi: 10.1016/j.nano.2012.07.002. Epub 2012 Jul 25. ABSTRACT Nanoparticle delivery into solid tumors is affected by vessel density, interstitial fluid pressure (IFP) and collagen, as shown in this article by contrasting the in vivo macroscopic quantitative uptake of 40 nm fluorescent beads in three tumor types.The fluorescence uptake was quantified on individual animals…Continue Reading Nanoparticle uptake in tumors is mediated by the interplay of vascular and collagen density with interstitial pressure
Improved tumor contrast achieved by single time point dual-reporter fluorescence imaging
J Biomed Opt. 2012 Jun;17(6):066001. doi: 10.1117/1.JBO.17.6.066001. ABSTRACT In this study, we demonstrate a method to quantify biomarker expression that uses an exogenous dual-reporter imaging approach to improve tumor signal detection. The uptake of two fluorophores, one nonspecific and one targeted to the epidermal growth factor receptor (EGFR), were imaged at 1 h in three…Continue Reading Improved tumor contrast achieved by single time point dual-reporter fluorescence imaging